INT313932

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.16
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 2.13
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
liver 4
Vms1 (Mus musculus)
Pain Link Frequency Relevance Heat
transdermal 42 50.00 Quite Low
Serotonin 2 12.60 Low Low
headache 4 5.00 Very Low Very Low Very Low
Pain 2 5.00 Very Low Very Low Very Low
cva 2 5.00 Very Low Very Low Very Low
Bioavailability 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Osteoporosis 2 100.00 Very High Very High Very High
Osteoporotic Fractures 2 100.00 Very High Very High Very High
Reprotox - General 3 4 95.40 Very High Very High Very High
Cancer 4 95.08 Very High Very High Very High
Reprotox - General 1 4 94.24 High High
Endometriosis (extended) 22 93.52 High High
Coagulation Disorder 2 92.52 High High
Hypertension 2 91.52 High High
Liver Disease 2 90.96 High High
Hypersensitivity 2 90.36 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
5 years) in women for whom the potential benefits outweigh the potential risks.1,11 The 5-year cut-off for HT is suggested because most women will experience spontaneous cessation of menopausal symptoms within 5 years of onset.1 Use of HT for longer durations may be appropriate in some women, such as those who judge the benefits of VMS relief to outweigh the potential risks after failing an attempt to discontinue HT, those with continued VMS who are also at high risk for osteoporotic fractures, and those requiring osteoporosis prevention who cannot take alternative therapies.2 Several weeks may be required to determine the efficacy of HT in treating VMS.5 Contraindications to the use of HT include breast or estrogen-sensitive cancers, undiagnosed vaginal bleeding, endometrial hyperplasia, blood clotting disorder, hypertension, liver disease, hypersensitivity to the active or excipient compounds in HT.1
Positive_regulation (required) of Positive_regulation (continued) of VMS in liver associated with coagulation disorder, endometriosis (extended), hypersensitivity, osteoporosis, osteoporotic fractures, liver disease, reprotox - general 3, cancer, hypertension and reprotox - general 1
1) Confidence 0.16 Published 2010 Journal Int J Gen Med Section Body Doc Link PMC2880349 Disease Relevance 1.09 Pain Relevance 0
5 years) in women for whom the potential benefits outweigh the potential risks.1,11 The 5-year cut-off for HT is suggested because most women will experience spontaneous cessation of menopausal symptoms within 5 years of onset.1 Use of HT for longer durations may be appropriate in some women, such as those who judge the benefits of VMS relief to outweigh the potential risks after failing an attempt to discontinue HT, those with continued VMS who are also at high risk for osteoporotic fractures, and those requiring osteoporosis prevention who cannot take alternative therapies.2 Several weeks may be required to determine the efficacy of HT in treating VMS.5 Contraindications to the use of HT include breast or estrogen-sensitive cancers, undiagnosed vaginal bleeding, endometrial hyperplasia, blood clotting disorder, hypertension, liver disease, hypersensitivity to the active or excipient compounds in HT.1
Positive_regulation (risk) of Positive_regulation (continued) of VMS in liver associated with coagulation disorder, endometriosis (extended), hypersensitivity, osteoporosis, osteoporotic fractures, liver disease, reprotox - general 3, cancer, hypertension and reprotox - general 1
2) Confidence 0.16 Published 2010 Journal Int J Gen Med Section Body Doc Link PMC2880349 Disease Relevance 1.04 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox